Quinta is an innovative and trusted world leader in pharmaceutical analysis, R&D and clinical testing in both human and veterinary medicinal products.
Offering a range of services spanning the whole pharmaceutical spectrum, Quinta possesses unrivaled expertise across analytical services, clinical studies and more.
Proudly based in Central Europe, with partners in the EU, US and Asia, Quinta has 200 experienced in-house professionals ready to support your projects.
Roman Grunt graduated from Czech Technical University in Prague, Faculty of Mechanical Engineering, and London Business School, where he studied Corporate Finance. Since 1996, he worked at Ernst & Young in Prague and Zurich. In 2000, he held several financial positions at Zentiva, participated in acquisitions in Slovakia, Romania and Turkey. During 2008, he became the CFO of Eczacibasi-Zentiva Turkey. Later, during 2010, he joined CEZ Turkey as the CFO. In autumn 2013, he became the General Director of the company FARMAK and since 2017, he has held the position of CEO of QUINTA-ANALYTICA.
Marcela Písačková studied chemistry at Charles University in Prague. She has completed a course Qualified person in the pharmaceutical industry and postgraduate courses Good Control Laboratory Practice and Pharmaceutical Analytical Control. She joined QUINTA-ANALYTICA in 1999 as a research worker and has since gained experience in many professional positions including a project coordinator and the Head of quality assurance. Since 2017, she has held the position of the Director of Operations responsible for pharmaceutical and bioanalytical analyses.
Jiří Raška is a graduate of Physical Chemistry from the University of Pardubice, where he also later completed his doctoral studies in the same field. From 2004 he worked as Head of QC in the pharmaceutical manufacturing company Contipro Group. From 2006-2008 he was Head of QC and Project Manager with the service provider Lunaria. From 2008–2013 he was Chief Production Officer and Commercial Director at IREL. From 2013-2018 he was Commercial Director of Czech based company FARMAK, manufacturer of APIs and intermediates for pharmaceutical industry. Since 2018 Jiří has been working for QUINTA-ANALYTICA as Chief Commercial Officer and is responsible for the company's business and marketing activities.
Martin Mička graduated from the University of Economics in Prague, Faculty of International Relations, with a minor specialization in Faculty of Business Administration. Since 2003 he held different senior financial positions in Zentiva Czech Republic, participated in the first IPO in Eastern Europe. In 2009 he joined bio-pharmaceutical company Actelion as Finance manager for Czech & Slovak Republic and since 2015 he worked as CEO. From September 2022 he took over the position of CFO at QUINTA-ANALYTICA.
Starting in the industry 30 years ago at the Charles University in Hradec Králové, CZ, Dr. Miroslav Janoušek dedicated his career-to-date at Zentiva where he served as a member of the corporate senior management team. Holding positions of responsibility across Quality, Regulatory, and Pharmacovigilance, he played a key part in the building of a highly renowned quality system and contributed to the Regulatory Affairs function in different stages of Zentiva's development. Enabling it to grow from a regional player to the global Gx business of Sanofi. Deeply involved in projects in Europe, Latin America, Southeast Asia & the Middle East throughout his career, he contribute to enhancing Quinta's team and ensuring we remain a leading provider of high quality analytical and clinical services for pharmadevelopment and manufacturing.
Robert Khaddour graduated from the University of Chemistry and Technology Prague, Faculty of Electrical Engineering. From 2001, he worked as a computer network administrator at the Institute of plasma physics. He joined QUINTA-ANALYTICA in 2002 as an IT manager and later became the Head of the technical department.
Romana Šnajperková graduated from the University of Jana Evangelisty Purkyně in Ústí nad Labem, Faculty of Social and Economic Studies, with a specialization in Social Policy. Since 2004 she held various HR positions across different HR functional areas. Namely in MAFRA media house, where she was responsible for Compensation and Benefits and Training and development activities. In 2015 she joined IBM, an international technology company, as HR Operations leader for Czech republic, moving to CEE HR Business Partner role and finishing as EMEA Employee Concerns Partner. From August 2022 she took over the position of HR Manager at QUINTA-ANALYTICA.
Richard Viskup graduated from the Comenius University in Bratislava, Faculty of Pharmacy, with a specialization in clinical pharmacy. Since 1997 he held different positions in R&D and project management in companies like PLIVA-Lachema, VUAB Pharma or Glenmark Pharmaceuticals. In 2012 he became Product Portfolio Manager at Apotex and in 2018 he worked as Business Development Director at Farmak. He joined QUINTA-ANALYTICA in 2022 as the Head of Quality Assurance.
After graduating from the University of Chemistry and Technology (UCT) in Prague, he worked for 36 years in the pharmaceutical industry. From 1990, he worked as the CEO of the largest pharmaceutical company and founded the new pharmaceutical industry in the Czech Republic. He undergone privatization (MBO) with the company Léčiva (renamed to Zentiva in 2003), carried out three major acquisitions of pharmaceutical companies (Slovakia, Romania, Turkey), carried out the first IPO on the Prague Stock Exchange since 1990 and then left the executive post after the acquisition by the multinational corporation Sanofi. In 2010, he received the Medal of Merit in the Economic Area from the President of the Czech Republic Václav Klaus. He has been a member of management boards of UCT and Charles University Prague since 2010. He is also a member of the advisory body at IOCB Prague, and was a member of BOD of the multinational company Actavis in 2013-2015.
After graduating from the Faculty of Technical and Nuclear Sciences of the Czech Technical University in Prague and postgraduate education at the Institute of Physical Chemistry of the Czechoslovak Academy of Sciences, he worked in various positions at the Research Institute for Pharmacy and Biochemistry in Prague. He later worked for the company Zentiva as the Director and Vice President for Research and Development. In 2011-2015 he was the Chairman of the Control Board of the Grant Agency of the Czech Republic. Today he provides expert consultations in the pharmaceutical industry. He is the author and co-author of more than 50 publications focused on the fields of quantum chemistry, relations between the structure and activity and pharmacokinetics.
Vit is currently acting as an Independent Consultant in the area of Regulatory Science and Clinical Development. Vit is profoundly skilled in the area of Clinical Development strategies/study, design/data mining, scientific support/evaluation, and data interpretation which he gained in multinational pharmaceutical companies, e.g. Pharminvent, Sanofi, Zentiva Inhalation Product and Zentiva. His background includes over 19 years of research experience covering areas of clinical pharmacology and phase I as well as phase II and III studies particularly in inhalation drug development, generic development and pain and obesity management. Educated at the 3rd faculty of medicine in Charles University and resident at the Bulovka hospital department of infectious disease, Vit also served a 3-year tenure as a Postdoctoral Research Fellow at the Health Science Center, University of Tennessee in the US. As a professional, Vit had facilitated the design, strategic development and data mining of bioequivalence, pharmacodynamics and clinical studies which led to numerous, successful market authorizations. Vit is also founder and organizer of BioBridges, a conference platform for professionals from pharmaceutical development, clinical/bioequivalence development and regulatory agencies.
Graduate of Faculty of Chemistry at Moscow State University. He worked at Institute of Macromolecular Chemistry of Czechoslovak Academy of Sciences and at Research Institute for Pharmacy and Biochemistry, Prague where he established laboratory of mass spectroscopy. In 1997 he found the company QUINTA-ANALYTICA s.r.o. where he was acting as a President between 1997-2006. In past he used active member of several scientific societies as J.M. Marci Spectroscopic Society, Czech Mass Spectrometry Group, German Mass Spectrometry Group etc. He is the author and co-author of more than 100 publications focused on the fields of mass spectrometry, trace analysis, analysis of drugs and metabolites and more. During his career, he was appointed as Study Director for more than 350 BE/BA clinical studies. Today he provides expert consultations to QUINTA-ANALYTICA s.r.o. as a member of it's Scientific Advisory Board.
Kay O’Shea holds a BSc degree in Industrial Chemistry from University of Limerick, Ireland, 1987. She has worked for 32 years in the Pharmaceutical sector in various roles in Regulatory Affairs, R&D, Project Management and Clinical research. Together with her then business partner, Kay ran her own Regulatory Affairs consultancy company, Ivowen for 9 years before joining EirGen Pharma in 2010 where she held the role of Head of Scientific Affairs as part of the Senior Leadership Team until her departure in June 2019. As part of her role at EirGen, Kay was responsible Regulatory and Clinical Affairs and for setting up a Project Management Office (PMO) for the company to enable delivery of projects on multiple platforms including Oral Solid Dose (OSD), Sterile Fill Finish (aseptic line), innovative Veterinary drugs in the small animal space and innovative modified release OSD formulations for EirGen’s parent company, OPKO. Various other roles throughout those 32 years included working as an analytical development chemist in a laboratory at generics company, Clonmel Healthcare (platforms included OSD and oral liquids), managing an inhalations R&D laboratory at IVAX and managing a Regulatory Affairs department including management of Bioequivalence studies and an R&D laboratory at Niche Generics.
As holders of both GMP, GLP and GCP certifications for human medicinal products, and GMP certification for veterinary medicinal products, Quinta are regularly, and successfully, audited by the State Institute for Drug Control (SÚKL) and US FDA.
All of our licenses and certifications are available for download below.
Please use the contact details or form below.
+420 242 454 311